News | February 21, 2022
Corbevax receives EUA for 12-18 age group
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
The recommendation has been sent to the DCGI for approval
Corbevax is administered through an intramuscular route with two doses scheduled 28 days apart and is stored between 2 degrees celsius to 8 degrees celsius
Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
It plans to deliver over 300 million doses to the Indian government
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
Equity raise to finance growth and investments in the biological space
The country’s vaccine production has more than doubled since April and is set to touch 300 million doses next month
Subscribe To Our Newsletter & Stay Updated
